According to the US Orange Book, it was first approved in the US on 20 April 2000. Patent numbers 5733919; 5965581 and 5972967 all expired in October 2016. Patent 5978698 expired in October 2017. Patent 6136794 expired in January 2019. Patent 6770660 expires in June 2023. References
Further reading
Hartman GD, Egbertson MS, Halczenko W, Laswell WL, Duggan ME, Smith RL, Naylor AM, Manno PD, Lynch RJ, Zhang G (November 1992). "Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors". Journal of Medicinal Chemistry. 35 (24): 4640–2. doi:10.1021/jm00102a020. PMID 1469694. External links
"Tirofiban". Drug Information Portal. U.S. National Library of Medicine.
Fissure of the nipple, colloquially referred to as "joggers nipple", is a condition that is the result of chafing of one or both nipples. This can occur in both men and women during physical exercise such as long-distance running where there is prolonged friction between the nipple and clothing. The issue is also commonly seen in surfers who do not wear rash guards or wetsuits. See also
Cracked nipple
List of cutaneous conditions

References


== External links ==